CONTEXT: Adiponectin is an adipocytokine associated with a variety of metabolic traits. These associations in human studies, in conjunction with functional studies in model systems, have implicated adiponectin in multiple metabolic processes. OBJECTIVE: We hypothesize that genetic variants associated with plasma adiponectin would also be associated with glucose homeostasis and adiposity phenotypes. DESIGN AND SETTING: The Insulin Resistance Atherosclerosis Family Study was designed to identify the genetic and environmental basis of insulin resistance and adiposity in the Hispanic- (n=1,424) and African-American (n=604) population. MAIN OUTCOME MEASURES: High quality metabolic phenotypes, e.g. insulin sensitivity (S(I)), acute insulin response (AIR), disposition index (DI), fasting glucose, body mass index (BMI), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and waist circumference, were explored. RESULTS: Based on association analysis of more than 40 genetic polymorphisms in the adiponectin gene (ADIPOQ), we found no consistent association of ADIPOQ variants with plasma adiponectin levels and adiposity phenotypes. However, there were two promoter variants, rs17300539 and rs822387, associated with plasma adiponectin levels (P=0.0079 and 0.021, respectively) in the Hispanic-American cohort that were also associated with S(I) (P=0.0067 and 0.013, respectively). In contrast, there was only a single promoter SNP, rs17300539, associated with plasma adiponectin levels (P=0.0018) and fasting glucose (P=0.042) in the African-American cohort. Strikingly, high impact coding variants did not show evidence of association. CONCLUSIONS: The lack of consistent patterns of association between variants, adiponectin levels, glucose homeostasis, and adiposity phenotypes suggests a reassessment of the influence of adiponectin in these pathways.
CONTEXT: Adiponectin is an adipocytokine associated with a variety of metabolic traits. These associations in human studies, in conjunction with functional studies in model systems, have implicated adiponectin in multiple metabolic processes. OBJECTIVE: We hypothesize that genetic variants associated with plasma adiponectin would also be associated with glucose homeostasis and adiposity phenotypes. DESIGN AND SETTING: The Insulin Resistance Atherosclerosis Family Study was designed to identify the genetic and environmental basis of insulin resistance and adiposity in the Hispanic- (n=1,424) and African-American (n=604) population. MAIN OUTCOME MEASURES: High quality metabolic phenotypes, e.g. insulin sensitivity (S(I)), acute insulin response (AIR), disposition index (DI), fasting glucose, body mass index (BMI), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and waist circumference, were explored. RESULTS: Based on association analysis of more than 40 genetic polymorphisms in the adiponectin gene (ADIPOQ), we found no consistent association of ADIPOQ variants with plasma adiponectin levels and adiposity phenotypes. However, there were two promoter variants, rs17300539 and rs822387, associated with plasma adiponectin levels (P=0.0079 and 0.021, respectively) in the Hispanic-American cohort that were also associated with S(I) (P=0.0067 and 0.013, respectively). In contrast, there was only a single promoter SNP, rs17300539, associated with plasma adiponectin levels (P=0.0018) and fasting glucose (P=0.042) in the African-American cohort. Strikingly, high impact coding variants did not show evidence of association. CONCLUSIONS: The lack of consistent patterns of association between variants, adiponectin levels, glucose homeostasis, and adiposity phenotypes suggests a reassessment of the influence of adiponectin in these pathways.
Authors: A H Kissebah; G E Sonnenberg; J Myklebust; M Goldstein; K Broman; R G James; J A Marks; G R Krakower; H J Jacob; J Weber; L Martin; J Blangero; A G Comuzzie Journal: Proc Natl Acad Sci U S A Date: 2000-12-19 Impact factor: 11.205
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: N D Palmer; C D Langefeld; J T Ziegler; F Hsu; S M Haffner; T Fingerlin; J M Norris; Y I Chen; S S Rich; T Haritunians; K D Taylor; R N Bergman; J I Rotter; D W Bowden Journal: Diabetologia Date: 2009-11-10 Impact factor: 10.122
Authors: Nicholette D Palmer; Josyf C Mychaleckyj; Carl D Langefeld; Julie T Ziegler; Adrienne H Williams; Michael Bryer-Ash; Donald W Bowden Journal: Diabetes Res Clin Pract Date: 2009-11-20 Impact factor: 5.602
Authors: Anthony J G Hanley; Donald Bowden; Lynne E Wagenknecht; Aarthi Balasubramanyam; Carl Langfeld; Mohammed F Saad; Jerome I Rotter; Xiuqing Guo; Yii-Der I Chen; Michael Bryer-Ash; Jill M Norris; Steven M Haffner Journal: J Clin Endocrinol Metab Date: 2007-04-10 Impact factor: 5.958
Authors: Meredith A Bostrom; Barry I Freedman; Carl D Langefeld; Lingyi Liu; Pamela J Hicks; Donald W Bowden Journal: Diabetes Date: 2008-12-03 Impact factor: 9.461
Authors: Jacklyn N Hellwege; Nicholette D Palmer; W Mark Brown; Mark W Brown; Julie T Ziegler; S Sandy An; Sandy S An; Xiuqing Guo; Y-D Ida Chen; Ida Y-D Chen; Kent Taylor; Gregory A Hawkins; Maggie C Y Ng; Elizabeth K Speliotes; Carlos Lorenzo; Jill M Norris; Jerome I Rotter; Lynne E Wagenknecht; Carl D Langefeld; Donald W Bowden Journal: Hum Genet Date: 2014-12-02 Impact factor: 4.132